Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: Is it the standard of care?

Current Opinion in Hematology

Volumn 17, Issue 2, 2010, Pages 133-138

  McClune, Brian L ^a   Weisdorf, Daniel J ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Acute myeloid leukemia; Elderly; Myelodysplastic syndrome; Nonmyeloablative; Reduced intensity conditioning; Transplantation

Indexed keywords

BUSULFAN; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW PURGING; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOTHERAPY; MORTALITY; MYELODYSPLASTIC SYNDROME; NATURAL KILLER T CELL; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT PLANNING; WHOLE BODY RADIATION;

AGE FACTORS; HUMANS; LEUKEMIA, MYELOID; MYELODYSPLASTIC SYNDROMES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 76749105216     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283366ba4     Document Type: Review

References (42)

1. Koreth K, SchlenkR, Kopecky K, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301:2349-2361.
2. Cornelissen J, van Putten W, Verdonck L, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109:3658-3666.
3. Vicente D, Lamparelli T, Gualandi F, et al. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transpl 2007; 40:349-354.
4. National Cancer Institute. Surveillance epidemiology and end results. SEER stat fact sheets acute myeloid leukemia. 17 November 2008. http://seer. cancer.gov/statfacts/html/amyl.html. [Accessed August 2009].
5. Ma X, Does M, Raza A, Mayne S. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109:1536-1542. (Pubitemid 46595689)
6. Farag S, Elder P, Marcucci G, et al. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged >or=50 years compared to younger adults with low-risk disease. Bone Marrow Transpl 2003; 31:87-93.
7. Yanada M, Emi N, Naoe T, et al. Allogeneic myeloablative transplantation for patients aged 50 years and over. Bone Marrow Transpl 2004; 34:29-35.
8. Appelbaum F, Gundacker H, Head D, et al. Age and acute myeloid leukemia. Blood 2006; 107:3481-3485.
9. Kuendgen A, Germing U. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly. Cancer Treat Rev 2009; 35:97-120.
10. Cancer and Leukemia Group; Farag S, Archer K, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006; 108:63-73.
11. Giralt S, Thall P, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97:631-637.
12. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-763.
13. McSweeney P, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft versus tumor effects. Blood 2001; 97: 3390-3400.
14. Karanes C, Nelson GO, Chitphakdithai P, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 14:8-15.
15. Shapira M, Tsirigotis P, Resnick I, et al. Allogeneic hematopoietic stem cell transplantation in the elderly. Crit Rev Oncol Hematol 2007; 64:47-63.
16. Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19:2304-2312.
17. Luger S, Ringden O, Perez W, et al. Similar outcomes using myeloablative versus reduced-intensity and nonmyeloablative allogeneic transplant preparative regimens for AML or MDS: from the Center for International Blood and Marrow Research [abstract]. Blood 2008; 112:348.
18. Ringden O, Labopin M, Ehninger G, et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27:4570-4577.
19. Hegenbart U, Niederwieser D, Sandmaier B, et al. Treatment for acute myelogenous leukemia by low-dose, total-body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24:444-453.
20. Oran B, Giralt S, Saliba R, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transpl 2007; 13:454-462. (Pubitemid 46421890)
21. Gyurkocza B, Storb R, Storer B, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with de novo and secondary acute myeloid leukemia [abstract]. Blood 2008; 112:149.
22. Schetelig J, Bornhauser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26:5183-5191.
23. Valcarcel D, Martino R, Caballero D, et al. Sustained remission of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-ver-sus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26:577-584.
24. Majhail N, Brunstein C, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transpl 2008; 14:282-289.
25. McClune B, Weisdorf D, DiPersio J, et al. Nonmyeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Research [abstract]. Blood 2008; 112:346.
26. Guilfoyle R, Demers A, Bredeson C, et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43:133-139.
27. Sorror M, Storer B, Sandmaier B, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112:1992-2001.
28. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:865-872.
29. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-383.
30. Sorror M, Maris M, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106:2912-2919.
31. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110:4606-4613.
32. Majhail NS, Brunstein CG, McAvoy S, et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 2008; 14:985-992.
33. Defor T, Majhail N, Weisdorf D, et al. A modified comorbidity index for hemato-poietic cell transplantation. Bone Marrow Transpl 2009 [Epub ahead of print]. http://www.nature.com/bmt/journal/vaop/ncurrent/pdf/bmt2009275a.pdf. [Accessed 5 October 2009].
34. Riley J, June C, Blazar B. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 2009; 30:656-665.
35. Kohrt H, Turnbull B, Heydari K, et al. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reaction after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood 2009; 114:1099-1109.
36. Pillai AB, George TI, Dutt S, et al. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. Blood 2009; 113:4458-4467.
37. Battaglia M, Stabillini A, Roncarolo M. Rapamycin selectively expands CD4+ CD24+FoxP3+ regulatory T cells. Blood 2005; 105:4742-4748.
38. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009; 9:324-337.
39. Rizzieri D, Storms R, Nikcevich D, et al. Safety trial of NK cell enhanced donor lymphocyte infusions from a 3-5/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation [abstract]. Blood 2008; 112:342.
40. Cooley S, Gada P, McKenna D, et al. Successful haploidentical hematopoietic cell engraftment using a nonmyeloablative preparative regimen including natural killer (NK) cells [abstract]. Blood 2008; 112:827.
41. Hsu K, Keever-Taylor C, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105:4878-4884.
42. Cooley S, Trachtenberg E, Bergemann T, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009; 113:726-732.